A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis
详细信息 查看全文
- 作者：Jizheng Qin (1) (2)
Hongwei Liang (3)
Dongquan Shi (1) (2)
Jin Dai (1) (2)
Zhihong Xu (1) (2)
Dongyang Chen (1) (2)
Xi Chen (3)
Qing Jiang (1) (2) - 关键词：Deep vein thrombosis ; MicroRNA ; Biomarker ; Serum
- 刊名：Journal of Thrombosis and Thrombolysis
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：39
- 期：2
- 页码：215-221
- 全文大小：318 KB
- 参考文献：1. Stulberg BN, Insall JN, Williams GW, Ghelman B (1984) Deep-vein thrombosis following total knee replacement: an analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am 66:194鈥?01
2. Stringer MD, Steadman CA, Hedges AR et al (1989) Deep vein thrombosis after elective knee surgery. J Bone Joint Surg Br 71:492鈥?97
3. Warwick D, Williams MH, Bannister GC (1995) Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 77:6鈥?0
4. Stein PD, Henry JW (1995) Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108:978鈥?81 CrossRef
5. Lieberman JR, Geerts WH (1994) Prevention of venous thromboembolism after total hip and knee arthroplasty. J Bone Joint Surg Am 76:1239鈥?250
6. Cohen SH, Ehrlich GE, Kauffman MS, Cope C (1973) Thrombophlebitis following knee surgery. J Bone Joint Surg Am 55:106鈥?12
7. Lynch AF, Bourne RB, Rorabeck CH, Rankin RN, Donald A (1988) Deep vein thrombosis and continuous passive motion after total knee arthroplasty. J Bone Joint Surg Am 70:11鈥?4
8. Turpie AG, Levine MN, Hirsh J et al (1986) A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315:925鈥?29 CrossRef
9. Hull RD, Raskob GE, Gent M et al (1990) Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 263:2313鈥?317 CrossRef
10. Hoek JA, Nurmohamed MT, Hamelynck KJ et al (1992) Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 67:28鈥?2
11. Coombes R (2005) Venous thromboembolism caused 25,000 deaths a year, say MPs. BMJ 330:559 CrossRef
12. Nosaka M, Ishida Y, Kimura A et al (2011) Absence of IFN-纬 accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice. J Clin Invest 121:2911鈥?920 CrossRef
13. Colwell CW Jr, Berkowitz SD, Lieberman JR et al (2005) Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 87:2169鈥?177 CrossRef
14. Francis CW, Berkowitz SD, Comp PC et al (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349:1703鈥?712 CrossRef
15. Francis CW, Davidson BL, Berkowitz SD et al (2002) Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 137(8):648鈥?55 CrossRef
16. Heit JA, Berkowitz SD, Bona R et al (1997) Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 77(1):32鈥?8
17. Hull RD, Pineo GF, Francis C et al (2000) Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med 160(14):2199鈥?207 CrossRef
18. Hamulyak K, Lensing AW, van der Meer J et al (1995) Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 74(6):1428鈥?431
19. Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA (2002) Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 136:865鈥?72 CrossRef
20. Ruvkun G (2008) The perfect storm of tiny RNAs. Nat Med 14:1041鈥?045 CrossRef
21. Esquela-Kerscher A, Slack FJ (2006) Oncomirs鈥攎icroRNAs with a role in cancer. Nat Rev Cancer 6:259鈥?69 CrossRef
22. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857鈥?66 CrossRef
23. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513鈥?0518 CrossRef
24. Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997鈥?006 CrossRef
25. Bonauer A, Carmona G, Iwasaki M et al (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710鈥?713 CrossRef
26. Hoekstra M, van der Lans CAC, Halvorsen B et al (2010) The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 394(3):792鈥?97 CrossRef
27. Bates SM, Jaeschke R, Stevens SM et al (2012) Diagnosis of DVT: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e351S鈥揺418S
28. Chen X, Hu Z, Wang W et al (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130:1620鈥?628 CrossRef
29. Liu R, Zhang C, Hu Z et al (2011) A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47:784鈥?91 CrossRef
30. Mattie MD, Benz CC, Bowers J et al (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24 CrossRef
31. Uchino K, Takeshita F, Takahashi RU et al (2013) Therapeutic Effects of MicroRNA-582-5p and -3p on the inhibition of bladder cancer progression. Mol Ther 21:610鈥?19 CrossRef
32. Long G, Wang F, Duan Q et al (2012) Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PLoS ONE 7:e50926 CrossRef
33. Deng H, Guo Y, Song H et al (2013) MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518:351鈥?59 CrossRef
34. Mao JH, Zhou RP, Peng AF et al (2012) microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett 4:1125鈥?129
35. Cheng Y, Kuang W, Hao Y et al (2012) Downregulation of miR-27a* and miR-532-5p and upregulation of miR-146a and miR-155 in LPS-induced RAW264.7 macrophage cells. Inflammation 35:1308鈥?313 CrossRef
36. Willeit P, Zampetaki A, Dudek K et al (2013) Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 112:595鈥?00 CrossRef - 作者单位：Jizheng Qin (1) (2)
Hongwei Liang (3)
Dongquan Shi (1) (2)
Jin Dai (1) (2)
Zhihong Xu (1) (2)
Dongyang Chen (1) (2)
Xi Chen (3)
Qing Jiang (1) (2)
1. The Center of Diagnosis and Treatment for Joint Disease, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Zhongshan Road 321, Nanjing, 210008, Jiangsu, People鈥檚 Republic of China
2. Joint Research Center for Bone and Joint Disease, Model Animal Research Center (MARC), Nanjing University, Nanjing, Jiangsu, People鈥檚 Republic of China
3. Jiangsu Engineering Research Center for microRNA Biology and Biotechnology, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, People鈥檚 Republic of China - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Cardiology
Hematology - 出版者：Springer Netherlands
- ISSN：1573-742X
文摘
Deep vein thrombosis is one of the common complications of orthopedic surgery, and pulmonary embolism which is one of its lethal complications can lead to mortality. Numerous efforts have been made to identify reliable and predictive biomarkers to detect the early signs of deep vein thrombosis. These studies have, however, not delivered any more informative candidates than the D-dimer that have been available. Cell-free microRNAs are present in a range of body fluids and have recently been shown to be useful biomarkers in many diseases. Therefore, the purpose of present study was to identify potential microRNA biomarkers of deep vein thrombosis that are present in serum. Serum samples were taken from 18 deep vein thrombosis patients and 20 age- and sex-matched controls. TaqMan microRNA array was used for an initial screening. Real-time PCR assay was implemented to confirm the concentrations of candidate microRNAs. We found that the serum levels of miR-582, miR-195 and miR-532 of deep vein thrombosis patients were higher than those of controls. miR-582 yielded an AUC (the areas under the ROC curve) of 0.959, and the other two microRNAs yielded an AUC of 1.000 in discriminating deep vein thrombosis from controls. These data hint that serum miR-582, miR-195 and miR-532 might have potential to be a novel noninvasive biomarkers for detection of DVT. And this is the first study suggesting that serum microNRAs might be used as biomarkers for deep vein thrombosis.